Navigation Links
Senetek PLC Announces 2009 Annual General Meeting Voting Results
Date:12/15/2009

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that shareholders had approved all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 14, 2009. Voting results were as follows:




    Description of            Votes        Votes         Votes         Non-
     Matter                    For        Against       Withheld      Votes
    --------------            -----       -------       --------      -----

    Election of  Kerry
     Dukes as Director      6,165,331    1,363,208       71,963      45,300
    Receipt of Annual
     Accounts for 2008
     with Directors'
     Report, auditors'
     report on those
     accounts and
     approve the last
     Directors'
     remuneration
     report                 6,717,147      795,815       87,540      45,300
    Appointment of
     Macias Gini &
     O'Connell LLP and
     BDO Stoy Hayward
     as the Company's
     independent
     auditors for 2009      6,663,843      796,173      140,486      45,300



"We are pleased with the results of the voting and we thank our shareholders for their support" stated Frank J. Massino, Senetek Chairman and CEO.

Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. As a result of this evaluation, Miller Tabak has made the following recommendations:

  • Consider changing the focus and direction of the Company and the current business model;
  • Identify potential business partners for merger and/or acquisition;
  • Raise additional capital.

The Company is currently in discussions with multiple investors and potential partners, however there is no assurance that these discussions will result in a completed transaction.

About Senetek PLC: Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites -- www.Senetekplc.com, www.Pyratine6.com and www.PyratineXR.com -- or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

SOURCE Senetek PLC


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Implements New Corporate Communication Policy
2. Senetek PLC Reports Second Quarter 2009 Financial Results
3. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
4. Senetek PLC Reports First Quarter 2009 Financial Results
5. Senetek PLC Reports 2008 Financial Results
6. Dynamics Group AG Publishes Research Report on Senetek
7. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
8. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
9. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
10. Senetek PLC Announces Key Personnel Appointments
11. Senetek PLC Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology: